Verrica Pharmaceuticals Inc. Deferred Tax Assets, Operating Loss Carryforwards
Verrica Pharmaceuticals Inc. (VRCA) had Deferred Tax Assets, Operating Loss Carryforwards of $58.66 million as of 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-11
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $58.66M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $54.01M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $37.17M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $29.77M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $58.66M 10-K · filed 2026-03-11 |
| 2024-12-31 | $54.01M 10-K · filed 2026-03-11 |
| 2023-12-31 | $37.17M 10-K · filed 2025-03-11 |
| 2022-12-31 | $29.77M 10-K · filed 2024-02-29 |
| 2021-12-31 | $31.51M 10-K · filed 2023-03-06 |
| 2020-12-31 | $23.88M 10-K · filed 2022-03-02 |
| 2019-12-31 | $14.37M 10-K · filed 2021-03-17 |
| 2018-12-31 | $6.91M 10-K · filed 2020-03-13 |
| 2017-12-31 | $1.95M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |